Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults

Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults

Lactobacillus johnsonii N6.2 mitigates the onset of type 1 diabetes (T1D) in biobreeding diabetes-prone rats, in part, through changes in kynurenine:tryptophan (K:T) ratios. The goal of this pilot study was to determine the safety, tolerance, and general immunological response of L. johnsonii N6.2 i...

Full description

Bibliographic Details
Main Authors: Guillermo E. Marcial, Amanda L. Ford, Michael J. Haller, Salvador A. Gezan, Natalie A. Harrison, Dan Cai, Julie L. Meyer, Daniel J. Perry, Mark A. Atkinson, Clive H. Wasserfall, Timothy Garrett, Claudio F. Gonzalez, Todd M. Brusko, Wendy J. Dahl, Graciela L. Lorca
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-06-01
Series:Frontiers in Immunology
Subjects:
Lactobacillus johnsonii
diabetes type I
probiotic
indoleamine-2,3-dioxygenase
microbiome
gastrointestinal symptom
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.00655/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2017.00655/full

Similar Items